JACC Advances · 2024 · 21 citations · 25 references
MedicineCardiologyClinical EpidemiologyEpidemiologic MethodsInflammationAcute Coronary SyndromesAtherosclerotic Cardiovascular Disease PreventionCardiovascular DiseaseCardiovascular Disease PreventionCardiovascular EpidemiologyCardiovascular RiskAtherosclerosis RiskAtherosclerotic Disease PreventionAtherosclerotic Risk AssessmentAtherosclerotic Risk StratificationCardiovascular Risk Stratification Using LipoproteinsQuality AssessmentSecondary Prevention Of DyslipidemiaSystematic Review Retrieval
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. The relationship between Lp(a) and major adverse cardiovascular events (MACE) in the context of high-sensitivity C-reactive protein (hs-CRP) levels remains controversial due to conflicting results from previous studies. Objectives: This systematic review and meta-analysis aimed to clarify the association between Lp(a) and risk of MACE across different hs-CRP levels in both primary and secondary prevention settings. Methods: We performed a systematic review by searching MEDLINE (PubMed), Embase (Ovid), Cochrane CENTRAL (Wiley), and Web of Science (Clarivate) from their inception to February 2024. Eligible studies reported the association of Lp(a) with MACE stratified by hs-CRP level. Data extraction and quality assessment were systematically conducted. Meta-analyses used random-effects models to compute pooled HRs for individuals with low (<2 mg/L) and high (≥2 mg/L) hs-CRP levels. Subgroup analyses were performed in primary and secondary prevention populations. Results: = 0.13). Conclusion: Elevated Lp(a) is associated with an increased risk of MACE independent of hs-CRP levels in both primary and secondary prevention populations.
25
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text